Author

Avrita Singh

Institution: Genentech

Observed institution: Genentech

OpenAlex ID: A5137104267

Fixed-duration subcutaneous (SC) mosunetuzumab (Mosun) in elderly/unfit patients with previously untreated diffuse large B-cell lymphoma (DLBCL): Interim analysis and patient-reported outcomes (PROs) from the phase 2 MorningSun study.

2026 · Ian W. Flinn, John M. Burke, et al. · Journal of Clinical Oncology · 1

Mosunetuzumab and Polatuzumab Vedotin as First-line Treatment for Large B Cell Lymphoma in Older Unfit or Frail Patients

2026 · Adam J. Olszewski, Herbert A. Eradat, et al. · Blood

Works count: 2

Citation count: 1

H-index: 1

I10-index: